Stada
Stada Arzneimittel AG, commonly known as Stada, is a prominent player in the global pharmaceutical industry, headquartered in Germany. Founded in 1895, the company has established a strong presence in Europe and beyond, focusing on the development, manufacturing, and marketing of generic and over-the-counter (OTC) products. Stada's core offerings include a diverse range of high-quality medicines, particularly in the areas of pain relief, dermatology, and respiratory health. What sets Stada apart is its commitment to quality and accessibility, ensuring that patients receive effective treatments at competitive prices. With a robust market position, Stada has achieved significant milestones, including strategic acquisitions that have expanded its product portfolio and geographical reach. The company continues to innovate, striving to meet the evolving needs of healthcare providers and patients worldwide.
DitchCarbon Score
How does Stada's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Stada's score of 13 is lower than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Stada's reported carbon emissions
In 2023, Stada Arzneimittel AG reported total carbon emissions of approximately 99,238,000 kg CO2e, comprising 42,696,000 kg CO2e from Scope 1 and 56,542,000 kg CO2e from Scope 2 emissions. Notably, the company also disclosed significant Scope 3 emissions, amounting to about 900,000,000 kg CO2e. Over the past few years, Stada has demonstrated a commitment to reducing its carbon footprint. In 2022, total emissions were approximately 109,954,000 kg CO2e, indicating a reduction in emissions by about 10,716,000 kg CO2e from 2022 to 2023. The company has set near-term reduction targets, although it has not committed to a net-zero goal as of now. Stada's emissions data reflects a consistent effort to monitor and manage its environmental impact within the pharmaceuticals, biotechnology, and life sciences sector. The company continues to engage in initiatives aimed at improving sustainability and reducing greenhouse gas emissions across its operations.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 31,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 112,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Stada is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
